Choosing the Right Nanoparticle Probe for SARS-CoV-2 Lateral Flow Assays

Lateral flow assays (LFAs) are invaluable diagnostic devices for the rapid testing of a wide range of biomarkers, including the SARS-CoV-2 nucleocapsid protein. Nanoparticle probe properties affect LFA processing speed, stability, sensitivity, cost, and the need for a reader. However, conjugation condition optimization and probe performance comparisons across different nanoparticles can be time consuming and labor intensive.

Download this white paper from nanoComposix to learn about the performance-based pros and cons of common nanoparticle probes for SARS-CoV-2 nucleocapsid protein LFAs, which researchers optimally conjugated and directly compared in a single large testing event.